Health.Global (HCG)

FairStock Score: 10/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

This is not the kind of business I would buy at ₹570.05. Market cap is ₹8,117 Cr, yet the company earns almost nothing: P/E is 298.31 and profit growth is -116.76%. The latest quarter tells the real story: sales of ₹633 Cr but a net loss of ₹-8 Cr. Benjamin Graham would say there is no margin of safety when you pay nearly 300 times earnings for a company that is losing money. Book value is ₹85.31, so paying 6.68 times book means you are paying a rich premium for tangible assets that are not generating acceptable returns. ROE is just 1.90% and ROCE is 8.56%, while debt-to-equity sits at 1.78. That combination is dangerous: high leverage, weak profitability, and zero dividend yield. The Piotroski F-Score of 4/9 reinforces the weak fundamental health. Sales growth of 13.34% is decent, and promoter holding of 63.77% does align interests, but growth is worthless if it never reaches the bottom line. The 52-week range of ₹513.30 to ₹804.65 shows how uncertain the market is about this business. This could be a turnaround story, but a value investor must wait for proof: consistent net profits, rising ROE, and lower debt. At a PEG of 22.36, expectations are far too high for a hospital business that is currently unprofitable. Price is what you pay, earnings are what you get. Right now, the earnings are simply not there.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer